Given that hypocomplementemia (low C3/C4) are detected in selected APS patients (8), and limited data exist investigating complement activation or CP-CAPs in APS, our study is timely to further investigate complement activation as a marker of disease activity and a risk assessment tool in different subgroups of aPL-positive patients. The gene discussed is C4A; the disease is autoimmune polyendocrinopathy.